Contineum Therapeutics (CTNM) Income from Continuing Operations (2023 - 2024)
Historic Income from Continuing Operations for Contineum Therapeutics (CTNM) over the last 2 years, with Q4 2024 value amounting to -$14.6 million.
- Contineum Therapeutics' Income from Continuing Operations fell 8747.59% to -$14.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$42.3 million, marking a year-over-year decrease of 28593.74%. This contributed to the annual value of -$42.3 million for FY2024, which is 28599.47% down from last year.
- Per Contineum Therapeutics' latest filing, its Income from Continuing Operations stood at -$14.6 million for Q4 2024, which was down 8747.59% from -$10.3 million recorded in Q3 2024.
- In the past 5 years, Contineum Therapeutics' Income from Continuing Operations registered a high of $41.6 million during Q2 2023, and its lowest value of -$14.6 million during Q4 2024.